FDA Aproval

Copy and Paste from TD Ameritrade Newswire

9:00a ET November 16, 2010 (Business Wire)

BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced  today that the Cancer Treatment Centers of America (CTCA) at Western  Regional Medical Center, located in the metropolitan Phoenix area, has  purchased a BSD-500 Hyperthermia System (BSD-500). CTCA at Western  Regional Medical Center is a state-of-the-art cancer facility that  provides the most advanced therapeutic resources in cancer treatment in  one location (http://www.cancercenter.com/western-hosp...  CTCA is a network of hospitals and one of the premier providers of  cancer care in the world. The CTCA hospitals were recently recognized by  the Commission on Cancer of the American College of Surgeons as  "offering the very best in cancer care." This will be the fourth BSD  Hyperthermia system purchased by CTCA, including two systems purchased  within the last two months.

"Hyperthermia is a highly specialized cancer treatment modality. When  used in combination with external beam radiation therapy, we will be  able to optimally treat a cancer with the goal of maximal containment of  the disease. By having this treatment available to us, we can offer our  patients the best therapeutic options available based on their  particular needs," said Lanceford Chong, MD, Radiation Oncologist at  CTCA.

For almost 30 years, CTCA has been on the leading edge of cancer  treatment with a personalized, whole-person care model. CTCA physicians  provide a full range of treatment options, including options for complex  and advanced stage cases, and utilizes innovative new techniques and  therapies to fight cancer on all fronts. CTCA is committed to  revolutionizing cancer care by providing the most advanced and effective  cancer treatments and supportive therapies available in order to treat  the cancer and improve the patient's treatment experience and quality of  life.

The BSD-500 Hyperthermia System is used to deliver therapeutic heating  (hyperthermia) using either non-invasive (external) hyperthermia, which  is delivered using antennas placed over the tumor, or interstitial  hyperthermia, which is delivered using antennas that are inserted into  the tumor, or a combination of both. The BSD-500 has received U.S. Food  and Drug Administration (FDA) pre-market approval (PMA) for the use of  hyperthermia in conjunction with radiation therapy to treat certain  tumors.

About Cancer Treatment Centers of America(R)

Founded in 1988, Cancer Treatment Centers of America (CTCA) provides a  comprehensive, patient-centered treatment model that fully integrates  traditional, state-of-the-art medical treatments with scientifically  supported complementary therapies such as nutrition, naturopathic  medicine, psychological counseling, physical therapy and spiritual  support to meet the special, whole-person needs of advanced stage cancer  patients. With a network of cancer treatment hospitals and community  oncology programs in Arizona, Illinois, Oklahoma, Pennsylvania and  Washington, CTCA encourages patients and their families to participate  in treatment decisions with its Patient Empowerment Medicine(SM) model.  For more information about Cancer Treatment Centers of America, go to  cancercenter.com.